Neither the anti‐FGFR3 antibody (5 mg kg−1) nor A2 (0.1 mg kg−1) exhibited significant tumor growth inhibition, and gemcitabine (20 mg kg−1) combined with cisplatin (2 mg kg−1) showed moderate therapeutic effects. This evidence concerns the gene FGFR3 and neoplasm.